Navigation Links
2-drug combo more effective in treating sarcomas, Moffitt Cancer Center study shows
Date:4/9/2013

tudies on sarcomas-related mutations, such as the p53 gene. They also showed that MK-1775 was an active inhibitor of Wee1 regardless of the p53 mutation status of the tumors in the cell lines tested.

"The toxic effect of Wee1 inhibition on sarcoma cells appeared to be independent of p53 mutation status following our testing sarcoma cell lines with different p53 mutations," Altiok said. "All of them were highly sensitive to MK-1775, suggesting that Wee1 inhibition may represent a novel approach in the treatment of sarcomas. But p53 status was not predictive of response to MK-1775 as a single agent."

Because of the success of that previous research, in the new study the Moffitt team investigated the benefits of MK-1775 alone compared to MK-1775 in combination with gemcitabine, a standard chemotherapy drug. They tested the combination in a number of sarcoma cell lines derived from patient tissues and then in animals modeled with osteosarcoma (bone sarcoma).

"The combination of MK-1775 and gemcitabine demonstrated a synergistic effect in sarcoma cells," explained Altiok. "MK-1775 alone caused tumor cell damage, but when used in combination with gemcitabine, there was increased cell death."

When the research team tested the combination in laboratory animals, they found that gemcitabine alone inhibited 40 percent of tumor growth. MK-1775 alone inhibited 50 percent of tumor growth. However, MK-1775 and gemcitabine together inhibited 70 percent of tumor cell growth.

"Our data demonstrated that MK-1775 alone and in combination with gemcitabine induces significant cell death in high-grade osteosarcoma cells," concluded the authors. "This finding lays an important foundation for future clinical trials with MK-1775, which is a well-tolerated, readily available targeted drug."


'/>"/>

Contact: Kim Polacek
kim.polacek@moffitt.org
813-745-7408
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Some patients with incurable tumors and BRCA mutations respond to new 2-drug combination
2. Mayo Clinic: 2-drug combination may slow deadly thyroid cancer
3. Moffitt researcher investigates 2-drug synergy to treat drug-resistant chronic myeloid leukemia
4. Combo Therapy Helps Knock Out Fungal Meningitis
5. E-commerce Software Provider Shopping Cart Elite Launches “Combo” Feature.
6. Study Examines Combo Chin, Nose Plastic Surgery
7. Combo Treatment Might Beat Epidural to Ease Labor: Study
8. Combo Inhaler May Give Better Relief for Some With Asthma
9. Niacin-Statin Combo May Cause Side Effects for Heart Patients
10. Acai Plus & Detox Plus Combo Pack Now Comes with Extra Information Guide with Every Purchase
11. Combo of Avastin, second drug shows promise fighting brain cancer, Mayo Clinic finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... KS (PRWEB) July 25, 2014 ... can be affected by the width of the alveolar ... hold the implant. A variety of methods exist, each ... subsequent augmentation techniques. The ridge-split graft is highlighted as ... The Journal of Oral Implantology offers a comparison ...
(Date:7/24/2014)... 25, 2014 Dr. Henry H. Ting, ... quality, has been appointed senior vice president and chief ... In his new role, he will oversee the hospital's ... has successfully led quality initiatives and interprofessional teams at ... teams for the Door-to-Balloon Alliance, a collaboration of more ...
(Date:7/24/2014)... Preventive Services Task Force recently recommended computerized tomography ... for cancer, but a potential problem with CT ... on the screening test, only to be deemed ... concern that this high false-positive rate will cause ... of National Lung Screening Trial participant responses to ...
(Date:7/24/2014)... off nighttime production of the hormone melatonin, renders breast ... cancer drug, says a new study by Tulane University ... Melatonin Disruption by Exposure to Light at Night Drives ... in the journal Cancer Research , is the ... success of tamoxifen in treating breast cancer. , , ...
(Date:7/24/2014)... (PRWEB) July 25, 2014 Voted one ... of the global clients, BellasDress focuses on providing its ... useful fashion information. Recently, the company has announced its ... in the new range is created according to the ... big discounts, up to 68% off. , As a ...
Breaking Medicine News(10 mins):Health News:A Comparison of Graft Techniques for the Alveolar Ridge Prior to Oral Implant 2Health News:A Comparison of Graft Techniques for the Alveolar Ridge Prior to Oral Implant 3Health News:NewYork-Presbyterian Hospital Names New Senior Vice President for Quality and Patient Safety 2Health News:NewYork-Presbyterian Hospital Names New Senior Vice President for Quality and Patient Safety 3Health News:Informed consent: False positives not a worry in lung cancer study 2Health News:Informed consent: False positives not a worry in lung cancer study 3Health News:Total darkness at night is key to success of breast cancer therapy -- Tulane study 2Health News:BellasDress Helps Brides Get High End Wedding Dresses for Their Romantic Weddings 2
... Nov. 3 Rib-X Pharmaceuticals, Inc.,("Rib-X" or the ... development of novel antibiotics for the treatment of,antibiotic-resistant ... Chief Executive Officer, is scheduled to present at ... Monday, November 10,2008 at 2:00pm EST. The conference ...
... TSX: BMR, TORONTO, Nov. 3 /PRNewswire-FirstCall/ - ... development and,commercialization of cancer therapies, announced today that ... of the Company, will present a,corporate update at ... being held in New York City from November ...
... Most frequent tumor sites were cervix, head and neck, ... -- An estimated 25,000 cases of cancers associated with ... District of Columbia between 1998 and 2003, U.S. officials ... that includes more than 100 different types, more than ...
... study comparing cancer rates of liver transplant patients to ... recipients face increased risks of developing cancer, especially non-Hodgkin,s ... the first year of follow-up and among younger transplant ... of Liver Transplantation , a journal by John ...
... new studies conclude that a review which claimed that homeopathy ... was seriously flawed. , George Lewith, Professor of ... indication of which trials were analysed nor of the various ... scientific practice. If we presume that homeopathy works for some ...
... genetic vulnerability , , MONDAY, Nov. 3 (HealthDay News) ... States that get a lot of precipitation appear to ... study suggests. , Because these children may spend more ... atmosphere to the ground, they might be exposed to ...
Cached Medicine News:Health News:Rib-X Pharmaceuticals, Inc. to Present at the Rodman & Renshaw 10th Annual Healthcare Conference 2Health News:Bradmer to present at Rodman & Renshaw Healthcare Conference 2Health News:Bradmer to present at Rodman & Renshaw Healthcare Conference 3Health News:U.S. Reported 25,000 Cases of HPV-Related Cancers Annually 2Health News:Liver transplant recipients have higher cancer risk 2Health News:New evidence for homeopathy 2Health News:Rainier Spots Show Higher Autism Rates 2Health News:Rainier Spots Show Higher Autism Rates 3Health News:Rainier Spots Show Higher Autism Rates 4
(Date:7/24/2014)... , July 24, 2014  IRIDEX Corporation (NASDAQ: ... release its second quarter 2014 financial results after the ... In conjunction with the release, the Company will host ... 5:00 p.m. Eastern Time on Thursday, July ... quarter and other business developments. Interested parties ...
(Date:7/24/2014)... , July 24, 2014 Omnicell, Inc. ... of medication and supply management solutions and analytics ... Thursday, July 31, to discuss the Company,s Second ... Second Quarter 2014 earnings conference call and webcastWhen: ... , Randall Lipps, chairman, president and chief executive ...
(Date:7/24/2014)... 2014  IGI Laboratories, Inc. (NYSE MKT: IG), a New ... its financial results for the second quarter ended June 30, ... Total revenues of $6.5 million in the second quarter of ... 2013 , Total revenues of $13.3 million for the ... over the same period in 2013 , Total revenues ...
Breaking Medicine Technology:Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7
... OXIS International, Inc. (OTC Bulletin Board: OXIS ... named former Wal-Mart executive Ken Eaton to its Board ... including three independent Directors. "I am very ... the OXIS International Board of Directors," said Anthony J. ...
... June 27, 2011 Pacira Pharmaceuticals, Inc ., ... company, today announced that it has been included in ... its comprehensive set of U.S. and global equity indexes ... 3000 Index measures the performance of the 3,000 largest ...
Cached Medicine Technology:OXIS International Names Former Wal-Mart Executive Ken Eaton to Board of Directors 2OXIS International Names Former Wal-Mart Executive Ken Eaton to Board of Directors 3Pacira Pharmaceuticals, Inc. Announces Inclusion in Russell 3000 Index 2Pacira Pharmaceuticals, Inc. Announces Inclusion in Russell 3000 Index 3
... lens, doctors have to make a trade off ... Now, with the Digital Wide Field lens ... both in one lens. This lens provides ... non-contact lens paired with the higher magnification required ...
... The Stryker Wedge Suture Anchors are titanium ... and styles. The Wedge anchors are simple ... and OR staff. The following sizes and ... Suture, 5.0mm Single Eyelet 2 Sutures, 5.0mm ...
... Suture Anchor is a 3.0mm single loaded ... (PLLA). The anchor barb catches on the ... until it "breaks" free. The small size ... also frequently used in rotator cuff repair ...
... absorbable co-polymer synthesized from all-natural ingredients: ... acid. Unlike the homopolymers in common ... (PLLA) or 100% poly-glycolic acid (PGA), ... crystallinity), meaning that its degradation is ...
Medicine Products: